# Pizarra — PT-pseudo_394e0b8dbeeb (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_394e0b8dbeeb
Task: 1

Encounter: Urology - outpatient on 04 Jan 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 9.2 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.17 ng/mL²
  - PSA velocity: 1.1 ng/mL/yr
  - Prior PSA: 10.1 ng/mL
  - Prostate volume: 53.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.78939086 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30), Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30), Benign prostatic hyperplasia
  - Current medication: atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, metoprolol, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 9.2 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 53 mL. DRE nodus. csPCa 0.79.

Vitals: weight 93 kg, height 164 cm, BMI 34.6, BP 114/71 mmHg, HR 70 bpm. Smoking: Current smoker (45 pack-yr).

Chief complaint: Elevated PSA progression alongside a newly identified PI-RADS 4 lesion on multiparametric MRI has necessitated specialist re-assessment.

History: Mr X, a 71-year-old harbour pilot (semi-retired), entered initial evaluation in early 2023 following an incidental PSA elevation. Lower urinary tract symptoms remain mild and are currently managed with tamsulosin, yielding an IPSS score of 7. He reports no haematuria or acute urinary retention. Cardiovascular comorbidities encompass coronary artery disease and hypercholesterolaemia, managed through a regimen of atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, and metoprolol. He is a Current smoker (45 pack-yr) but maintains physical activity by cycling roughly 30 kilometres three times weekly. Obesity (BMI >30) is present. He remains married and lives with his partner. An adult daughter handles his medical correspondence upon request. Aside from the urological investigations, he experiences stable bilateral knee discomfort stemming from years of deck work and recently visited a podiatrist for routine nail care. No systemic symptoms or unexplained weight loss are reported.

Physical examination: DRE — prostate: asymmetrically enlarged, firm texture, discrete nodule palpable in the right mid-gland. General examination remains unremarkable, with stable vital signs and no evidence of palpable lymphadenopathy or abdominal masses.

Patient info: harbour pilot (semi-retired); Married; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 8 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Podiatry — routine foot care.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.70 +/- 0.20   (95% CI 0.25-0.98)

Where the uncertainty comes from:
  - aleatoric  dA = 0.18  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.09  (few labelled cases resemble this one)
  - 3.6 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'supports': A +/- dA does not cross 0.5, but A +/- 1.96*dA does. There is a direction, not a conclusion. Measured accuracy in this tier: 0.67. Treat it as a weighted vote, not as a decision.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=1.0, psa=9.2, age=71.0, psad=0.17, dre_ord=1.0, vol=53.0, n_pmhx=4.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the PSA velocity (1.1 ng/mL/yr) or the prior PSA (10.1 ng/mL), which indicate a concerning trend, against the PI-RADS 4 score and the prior negative biopsy status. It also missed the context provided by the full mpMRI report, the PSA history trend, and the laboratory panel, which are crucial for assessing the clinical significance of the elevated PSA and the lesion characteristics.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests biopsy based on a high csPCa probability (0.789) and PI-RADS 4. However, the prior negative biopsy status might make the question "does he have cancer" inappropriate, as the current decision hinges on whether the new PI-RADS 4 lesion is clinically significant given the prior negative result. The PSA velocity (1.1 ng/mL/yr) suggests progression, which might warrant a different approach than the prior model assumed. The wide error bar (0.20) suggests high disagreement among similar cases, meaning the underlying features used by the prior are not perfectly predictive for this specific patient profile.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details the extent/characteristics of the PI-RADS 4 lesion, it would refine the risk assessment.
  <document> PSA history (trend) -> If the trend confirms significant progression, it would increase the urgency for intervention.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the initial evaluation or LUTS severity that influences the clinical threshold for biopsy.
  <document> laboratory results (full panel) -> This panel could provide context on other markers that might influence the decision threshold.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line - that is an honest result.

  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_394e0b8dbeeb", "radiology_report": "Subject: Multiparametric MRI Prostate | Date: 20 December 2024 | Institution: Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)\nClinical Context: 71-year-old male presenting with a PSA trajectory of 9.2 ng/mL and a previously documented negative biopsy bucket.\n\nFINDINGS:\nThe gland measures 53.0 mL in total volume. T2-weighted sequences identify a 12 mm hypointense focus within the right mid-gland, reaching toward the peripheral zone. Margins appear irregular with architectural disruption. Diffusion-weighted imaging demonstrates significant restriction paired with low ADC values, indicating increased cellularity. Dynamic contrast enhancement is early and focal compared to adjacent tissue. Seminal vesicles appear normal. There is no evidence of extraprostatic extension or pelvic lymphadenopathy.\n\nIMPRESSION:\nPI-RADS 4 lesion in the right mid-gland peripheral zone.\nProstate volume 53.0 mL yielding a PSA density of 0.17 ng/mL/mL.\ncsPCa predicted probability 0.78939086."}

  **psa_trend**
  {"case_id": "PT-pseudo_394e0b8dbeeb", "psa_trend": [{"date": "Apr 2023", "val": 7.0}, {"date": "Nov 2023", "val": 7.9}, {"date": "Jun 2024", "val": 6.5}, {"date": "Jan 2025", "val": 9.2}]}

  **previous_notes**
  {"case_id": "PT-pseudo_394e0b8dbeeb", "previous_notes": [{"date": "15 Jan 2023", "author": "Dr. E. Mulder (GP)", "text": "Initial laboratory workup in April 2023 flagged a PSA elevation of 6.1 ng/mL. The individual noted mild urinary hesitancy, though acute retention and haematuria were absent. Because of his age and the first elevation, clinicians arranged a follow-up PSA test six months later and initiated a urology referral for baseline evaluation."}, {"date": "06 Sep 2024", "author": "Dr. E. Mulder (GP)", "text": "Subsequent laboratory data collected in June 2024 showed a further rise to 10.1 ng/mL, prompting a repeat multiparametric MRI that located a suspicious focus. In light of the earlier negative biopsy, the steady upward PSA trend, and the present imaging results, specialist input was requested. The case was forwarded to the urology outpatient department for clinical re-assessment and to review targeted sampling options."}]}

  **laboratory_results**
  {"case_id": "PT-pseudo_394e0b8dbeeb", "laboratory_results": [{"name": "PSA", "val": "9.2 ng/mL", "date": "21 Nov 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.44 ng/mL", "date": "21 Nov 2024", "flag": ""}, {"name": "%Free PSA", "val": "16%", "date": "21 Nov 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "15.0 g/dL", "date": "21 Nov 2024", "flag": ""}, {"name": "WBC", "val": "7.5 x10^9/L", "date": "21 Nov 2024", "flag": ""}, {"name": "Platelets", "val": "310 x10^9/L", "date": "21 Nov 2024", "flag": ""}, {"name": "Creatinine", "val": "107 umol/L", "date": "21 Nov 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "21 Nov 2024", "flag": ""}, {"name": "Testosterone", "val": "8.5 nmol/L", "date": "21 Nov 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "63 U/L", "date": "21 Nov 2024", "flag": ""}, {"name": "LDH", "val": "160 U/L", "date": "21 Nov 2024", "flag": ""}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 4 lesion in the right mid-gland peripheral zone
  PSA velocity of 1.1 ng/mL/yr (from trend data)
  PSA rising from 10.1 ng/mL to 9.2 ng/mL (Note: The trend shows a rise from 6.5 to 9.2 over 1.5 years, and the current PSA is 9.2 ng/mL, which is high)

  AGAINST sampling this patient now:
  Prior biopsy was Negative
  csPCa predicted probability 0.78939086 (This is high, but the prior negative result is a counterpoint)

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the presence of a high-risk PI-RADS 4 lesion and a concerning PSA velocity, which contradicts the caution implied by the prior negative biopsy. This leans towards a strong recommendation for re-biopsy or targeted sampling.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports intervention due to the presence of a high-risk PI-RADS 4 lesion and a concerning PSA velocity of 1.1 ng/mL/yr. This finding is important because it contradicts the caution implied by the prior negative biopsy status. The decision is driven by the PI-RADS 4 score and the PSA trend, which together necessitate further tissue sampling.

Variables that carried weight: bx=decisive, age=noted, psa=decisive, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
